SL
ABBV icon

Salomon & Ludwin’s AbbVie ABBV Stock Holding History

Salomon & Ludwin’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
5,275
+41
+0.8% +$8.82K 0.11% 84
2026
Q1 		$1.09M Sell
5,234
-117
-2% -$26K 0.1% 86
2025
Q4 		$1.18M Sell
5,351
-494
-8% -$113K 0.1% 86
2025
Q3 		$1.37M Buy
5,845
+1,063
+22% +$216K 0.12% 79
2025
Q2 		$912K Hold
4,782
– – 0.09% 82
2025
Q1 		$1M Sell
4,782
-3
-0.1% -$583 0.11% 77
2024
Q4 		$850K Sell
4,785
-1
-0% -$184 0.09% 81
2024
Q3 		$945K Sell
4,786
-96
-2% -$17.9K 0.1% 83
2024
Q2 		$837K Sell
4,882
-2,545
-34% -$422K 0.09% 88
2024
Q1 		$1.35M Buy
7,427
+8
+0.1% +$1.38K 0.12% 81
2023
Q4 		$1.11M Hold
7,419
– – 0.12% 79
2023
Q3 		$1.11M Buy
7,419
+59
+0.8% +$8.66K 0.12% 79
2023
Q2 		$992K Sell
7,360
-10
-0.1% -$1.47K 0.11% 81
2023
Q1 		$1.17M Hold
7,370
– – 0.14% 70
2022
Q4 		$1.19M Buy
7,370
+8
+0.1% +$1.23K 0.15% 69
2022
Q3 		$988K Buy
7,362
+2,999
+69% +$430K 0.15% 60
2022
Q2 		$668K Buy
4,363
+245
+6% +$37.4K 0.1% 66
2022
Q1 		$668K Buy
4,118
+161
+4% +$23.4K 0.1% 56
2021
Q4 		$536K Buy
+3,957
New +$467K 0.08% 61
2020
Q2 		– Sell
-268
Closed -$20K – 67
2020
Q1 		$20K Sell
268
-949
-78% -$80.8K 0.01% 137
2019
Q4 		$108K Buy
1,217
+800
+192% +$66.4K 0.02% 75
2019
Q3 		$32K Hold
417
– – 0.01% 117
2019
Q2 		$30K Sell
417
-34
-8% -$2.67K 0.01% 113
2019
Q1 		$36K Buy
451
+34
+8% +$2.78K 0.01% 99
2018
Q4 		$38K Buy
+417
New +$36.7K 0.01% 96

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Salomon & Ludwin's ABBV Position: Q2 2026 in Review

Salomon & Ludwin increased its AbbVie (ABBV) stake by 0.78% in Q2 2026, buying an estimated $8.82K and bringing the position to 5,275 shares worth $1.32M. The position accounts for 0.11% of the portfolio, ranked #84.

Salomon & Ludwin first reported a position in ABBV in Q4 2018 and has held it in 25 quarters since. The position peaked at $1.37M in Q3 2025. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Salomon & Ludwin held 5,275 shares of AbbVie worth $1.32M as of Q2 2026.
  • Salomon & Ludwin bought 41 AbbVie shares in Q2 2026, an estimated $8.82K.
  • AbbVie made up 0.11% of Salomon & Ludwin's portfolio in Q2 2026, its #84 holding.
  • Salomon & Ludwin first reported a position in AbbVie in Q4 2018 and has held it in 25 quarters since.
  • Salomon & Ludwin's AbbVie position peaked at $1.37M in Q3 2025.
  • 4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.